Radiation Research · 1998 · 11 citations · 24 references
MedicineEndocrinologyOncologyEndocrine OncologyRadiation DosimetryRadiobiologyBiological Effects Of RadiationBreast Cancer RadiobiologyMammary TumorsRadiation CarcinogenesisRadiation Risk AssessmentRadiation ToxicityAge-dependence Of RiskAge-specific Cancer IncidenceAge-specific Incidence PatternsCarcinogenesis Risk AssessmentEstrogen-dependent CarcinogenesisGamma Irradiation EffectsHormonal Carcinogen ExposureRadiation Carcinogenesis Risk
The effect of age at exposure on induction of mammary carcinoma was studied in female rats of the inbred WAG/Rij strain that were treated with estrogen. Groups of 40 animals were exposed to a single total-body dose of 1 or 2 Gy of 137Cs gamma radiation at age 8, 10, 12, 15, 22, 36 or 64 weeks. Hormone levels in the animals were increased by implantation of a pellet containing Estradiol-17beta 2 weeks prior to irradiation. Animals were killed when moribund. All mammary tumors were resected and classified histologically as carcinoma or fibroadenoma. The age-specific incidence of mammary carcinoma was compared with that in control groups of unirradiated estrogen-treated rats using lifetime statistical analysis with both parametric and nonparametric methods. The excess normalized risk of carcinoma was 7.7 for both 1 and 2 Gy in the age groups 8-15 weeks, with no significant differences between the age groups. However, in the age groups 22-64 weeks, the excess normalized risk decreased with increasing age at exposure. Irradiation at 64 weeks yielded fewer carcinomas than in the controls, with an excess normalized risk of -0.6 for both 1 and 2 Gy. The excess normalized risk was 10-80 in estrogen-treated controls compared to untreated rats. The present data agree with the results reported previously for estrogen-treated rats irradiated at ages 8 or 17 weeks with doses of 0.3 or 1.2 Gy. The reduced risk of radiation exposure at midlife observed in this study in hormone-treated rats has also been reported for animals not treated with estrogens. The present findings support the earlier conclusion that radiological screening for mammary cancer after the age of menopause will not increase the normal incidence of breast cancer. Estrogen treatment at midlife may increase the risk of breast cancer in women using replacement estrogens during and after menopause.
24
Breast cancer screening with mammography: overview of Swedish randomised trials
L. Nyström, Stig Wall, L. E. Rutqvist et al. · The Lancet · 1993 · 978 citations
C. Richard Dorn, Dee O. N. Taylor, Robert J. Schneider et al. · JNCI Journal of the National Cancer Institute · 1968 · 453 citations